Search alternatives:
significant estimated » significant estimates (Expand Search), significantly mitigated (Expand Search), significantly overestimated (Expand Search)
significant larger » significantly larger (Expand Search), significant barrier (Expand Search), significantly longer (Expand Search)
larger decrease » marked decrease (Expand Search)
Showing 1 - 20 results of 7,504 for search '(( significant estimated decrease ) OR ( significant larger decrease ))', query time: 0.34s Refine Results
  1. 1
    MS decreases the larger amplitude distribution in adult rats.

    MS decreases the larger amplitude distribution in adult rats. by Jesús David Ayala-Rodríguez (17364296)

    Published 2023
    Save to List
    Saved in:
  2. 2
    Estimates of average yearly citations of publications by scholars accused of scientific misconduct by retraction status and time.

    Estimates of average yearly citations of publications by scholars accused of scientific misconduct by retraction status and time. by Giulia Maimone (20833354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  3. 3
    Estimates of the average yearly citations per publication (including all publications) by scholar group, misconduct type, and time.

    Estimates of the average yearly citations per publication (including all publications) by scholar group, misconduct type, and time. by Giulia Maimone (20833354)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  4. 4
    Estimated parameters for distribution of basal area.

    Estimated parameters for distribution of basal area. by Alexandra M. Campbell (3284094)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  5. 5
    Relationship of amount of remittances and estimated probability of skilled delivery (adjusted model) n = 91.

    Relationship of amount of remittances and estimated probability of skilled delivery (adjusted model) n = 91. by Chelsea Ducille (21540080)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  6. 6
    Relationship of amount of remittances and estimated probability of skilled delivery with MAMA Kit (adjusted model) n = 105.

    Relationship of amount of remittances and estimated probability of skilled delivery with MAMA Kit (adjusted model) n = 105. by Chelsea Ducille (21540080)

    Published 2025
    Subjects:
    Save to List
    Saved in:
  7. 7
    A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity.

    A noxious temperature decrease without a prior increase produces a subtly larger decrease in pain intensity. by Benedict J. Alter (9745466)

    Published 2020
    Save to List
    Saved in:
  8. 8
    CBP per cumulative year for daratumumab and pembrolizumab per vial.

    CBP per cumulative year for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  9. 9
    S4 Fig -

    S4 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  10. 10
    S1 Fig -

    S1 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  11. 11
    S5 Fig -

    S5 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  12. 12
    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial.

    Scenario analysis for pembrolizumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  13. 13
    S3 Fig -

    S3 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  14. 14
    S6 Fig -

    S6 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  15. 15
    CBP per cumulative indication for daratumumab and pembrolizumab per vial.

    CBP per cumulative indication for daratumumab and pembrolizumab per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  16. 16
    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation.

    Inputs utilized in base-case and scenario analysis for daratumumab and pembrolizumab, both unadjusted and adjusted for PPP and inflation. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  17. 17
    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab.

    Implementation of indication-based pricing (10<sup>th</sup> scenario) for daratumumab and pembrolizumab. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  18. 18
    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial.

    Scenario analysis for daratumumab using a cumulative cost-based price per year per vial. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  19. 19
    Input parameters for the base-case analysis.

    Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:
  20. 20
    S2 Fig -

    S2 Fig - by R. J. S. D. Heine (17889199)

    Published 2024
    Subjects:
    Save to List
    Saved in:

Search Tools: